Is the targeted drug trametinib an effective treatment for kras mutation g12d?

The effectiveness of Trametinib (Trametinib) in the treatment of cancers with KRAS G12D mutations has not yet been fully confirmed. Although trametinib has been approved for other tumor types, such as malignant melanoma, non-small cell lung cancer, etc., its therapeutic effect for patients with KRAS G12D mutation-positive patients is still under study.

KRAS mutations have been one of the hardest targets in cancer research. MRTX 1133, a potential first-in-class oral KRAS G12D-selective inhibitor for clinical evaluation, is associated with an approximately 2.5-fold increase in prevalence compared to KRAS G12C mutations, for which there are currently no targeted oncology treatment options for these patients. MRTX 1133 demonstrates selective and reversible inhibition of kras 12d in its active and inactive states. Administration of MRTX 1133 resulted in significant tumor responses in preclinical KRAS G12D mutant pancreatic cancer models as well as lung and colorectal cancer models.

The original drug of Trametinib has been launched in China and is included in the scope of medical insurance. Only patients who meet the indications can choose to reimburse. The price of 2 mg*30 tablets is more than RMB 10,000. The original drug of Trametinib sold overseas is priced at more than RMB 7,000 (the price may fluctuate due to the exchange rate). There are also generic trametinib drugs produced in other countries overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 2mg*30 tablets produced by a Laos pharmaceutical factory is more than 2,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.